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Summary
Introduction: Leprosy patients may develop immune-mediated inflammatory
reactions, which are the main cause of nerve function impairment and disability.
Among them, Erythema Nodosum Leprosum (ENL) is a potentially life-threatening
systemic condition. There are few data on ENL-associated morbidity and mortality,
and the need of hospitalisation due to its complications.
Material and methods: We conducted a retrospective cohort study including
patients diagnosed at the Souza Arau´jo Outpatient Clinic, Rio de Janeiro. All patients
had a first ENL episode at the clinic or were admitted to the Evandro Chagas Hospital,
between 2005–2010. In 2014, we obtained the required data from the patients’ files to
describe ENL morbidity and mortality, including treatment-related adverse events.
Results: A total of 112 patients (72% male, median age at diagnosis 35 years, 83%
had lepromatous leprosy) developed ENL, among the 676 patients diagnosed with
leprosy during the study period. Most of the episodes were chronic and severe.
Patients were treated with thalidomide and corticosteroids. Half of the patients
receiving corticosteroids had adverse events. 14 patients were hospitalised, ten due to
ENL complications. Six patients died, four during the ENL episode. None of these
deaths could be considered directly caused by ENL or its treatment.
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Conclusion: In the group of patients studied, although a high morbidity due to the
reaction itself and to the adverse effects of its prolonged treatment was observed,
mortality due to ENL was not registered. Prospective studies are required in order to
recognise leprosy complications, such as ENL, as consequential causes of death.
Introduction
Brazil reported 26,875 cases of leprosy to the World Health Organization (WHO) in 2017 of
which 73·8% were multibacillary (MB) cases.1 The latter are patients with low cell-mediated
immunity to Mycobacterium leprae and have high bacterial loads with widespread
dissemination of organisms to tissues other than skin and peripheral nerves.
Leprosy can be complicated by inflammatory episodes called reactions, which are the
leading cause of nerve function impairment (NFI), the hallmark of the disease.2 Reversal
reactions and erythema nodosum leprosum (ENL) can occur before, during or after successful
completion of multi-drug therapy (MDT).3,4 ENL is a life-threatening, painful, systemic
disorder due to an inflammatory immune response to M. leprae antigen.5,6 It occurs in
patients with borderline lepromatous (BL) leprosy and lepromatous leprosy (LL). A bacterial
index greater than or equal to four is also a risk factor for ENL.7 ENL is characterised by the
development of crops of erythematous tender skin nodules, fever and inflammation in other
organs such as peripheral nerves, joints, bones, eyes, lymph nodes and testes.6
Although the first line therapy for ENL in most leprosy endemic countries is oral
corticosteroids,8 in Brazil, the Ministry of Health recommends the use of thalidomide. It has a
rapid onset of action for ameliorating ENL symptoms. Its use reduces the need for chronic
oral corticosteroids that produce important adverse effects. There is evidence to support the
use of thalidomide as a first line treatment for moderately severe and severe ENL.9
Thalidomide is prescribed in accordance with strict guidelines, which include a pregnancy
prevention plan for women with reproductive capacity.10 However, in some countries its use
is banned because of the risk of teratogenicity whilst in others it is only available at certified
centres (where its use may be further restricted to male patients or in-patients).11
A study of patients with ENL in Ethiopia, where thalidomide is not available, found
morbidity and mortality associated with corticosteroids treatment.12 There are few data on the
long-term outcomes for people treated for ENL. Patients treated with thalidomide or other
immunomodulating drugs might have different outcomes to those who receive corticosteroids.
A study at The Hospital for Tropical Diseases, London, in a cohort of 30 patients diagnosed
with ENL between 1996 and 2013, four had ENL for over 10 and up to 16 years.13
Patients at Souza Araujo Outpatient Clinic, a national referral centre, are treated with
either corticosteroids and/or thalidomide or with other drugs such as pentoxifylline,
minocycline or non-steroidal anti-inflammatory drugs. We studied the morbidity and
mortality associated with ENL in a retrospective study of patients with clinically diagnosed
ENL, between 2005 and 2014.
Methods and definitions
The Souza Arau´jo Outpatient Clinic is a reference centre for leprosy in Rio de Janeiro, Brazil.
All patients diagnosed for the first time with leprosy at the clinic or admitted to the Evandro
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Chagas Hospital, National Institute of Infectiology, Oswaldo Cruz Foundation, between 1st
January 2005 and 31st December 2010, were identified from the electronic database. Only
individuals who presented with or developed their first episode of ENL during the study
period and had complete medical records were included. Data were collected on demographic
and clinical characteristics; ENL clinical features, treatment and its adverse effects. The
cause of death was obtained from the medical records, from either the social worker (as
referred by the patient’s family) or the attending physician annotations.
MB Leprosy was diagnosed by the presence of acid fast bacilli in at least one of four/six
slit skin smear samples and skin lesion histopathology.10
ENL was defined as crops of erythematous, tender cutaneous or subcutaneous nodules,
plaques and/or papules in a patient with MB leprosy.6,14 Once the patients were diagnosed
with ENL, they started treatment with thalidomide, prednisone and/or pentoxifylline.8
An ENL episode was defined by the period of ENL treatment and the subsequent
treatment-free period for up to 89 days. Additional episode(s) occurring 90 days or more after
stopping treatment for a previous episode was defined as recurrent ENL. ENL duration could
be acute if it required treatment for less than 24 weeks, or chronic, if treated for 24 weeks or
longer (or where any interruption of treatment was for 89 days or less during this period).6
The episodes were classified into mild (less than 10 skin lesions), moderate (more than 10
skin lesions and no systemic symptoms), and severe (skin lesions with at least one other organ
system or neurological involvement).6
Fever was defined as a documented axillary temperature greater than 37·58C.
Neuritis was defined as tenderness, inflammation and enlargement of the peripheral nerve
trunks with or without NFI.2
A drug-related adverse event was present if a noxious and unintended response occurred
“at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for
modification of physiological function.”15
Anonymised data were extracted from the patients’ files in June 2014 using a standard
data collection template and entered into Excele. The data were analysed using Stata 14
(StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP).
Descriptive statistics were performed for sociodemographic and clinical variables. The
Chi-squared test (x2) was used to compare differences between groups.
Ethical approval was obtained from the Oswaldo Cruz Institute (CAAE
32884814.3.0000.5248), Evandro Chagas National Institute of Infectology (CAAE
32884814.3.3001.5262) and the London School of Hygiene and Tropical Medicine Research
Ethics Review Boards.
Results
During the study period, 676 patients were diagnosed with leprosy at Souza Arau´jo
Outpatient clinic; 300 (44·4%) were classified as MB. A total of 112 (37·3%) patients
(n ¼ 81, 72% male) had a first ENL episode between 2005–2010 (Table 1). Most of them
(n ¼ 93, 83%) were diagnosed with LL and treated with standard MDT for MB leprosy
(n ¼ 91, 81·3%). However, 21 (19%) patients received alternative MDT due to
contraindications for the use of dapsone. Only 24 (21%) patients had their HIV status
recorded, and two (2%) patients were HIV-positive. The median age at onset of ENL was 34·8
years (Range ¼ 13·4–79·6). 19 women (61%) were of childbearing age, under 40 years old,
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at the time of their first ENL diagnosis. The first episode was most frequently diagnosed
during leprosy treatment (47% of the patients), mainly during the first 6 months of MDT
(n ¼ 36, 67·9%).
Table 2 shows the clinical features of the first ENL episode. Most patients (n ¼ 94, 84%)
experienced ENL as a multisystem disorder, mainly due to oedema (n ¼ 63, 56%), fever
(n ¼ 52, 46%) and arthritis (n ¼ 46, 41%). According to skin lesion morphology, most
patients had nodules (n ¼ 106, 95%). Complications of skin lesions during the first ENL
episode were observed in only six (5·4%) of the patients, five (83%) with ulceration and one
(17%) with necrosis. Five (4·5%) patients had mild, 13 (11·6%) moderate and 94 (84%)
severe ENL. Most of the patients (n ¼ 71, 63·4%) had only one ENL episode during the
study period. The two HIV-positive patients had their first episode during MDT, were treated
with thalidomide and prednisone, and had no complications due to ENL.
The median interval between starting treatment for ENL and no longer requiring
treatment was 35 months. However, one person required treatment for a period of almost
9 years. There was no significant difference between men and women concerning first ENL
treatment duration.
Regarding the treatment used during the first episode, 98 (88%) patients received
thalidomide (between 100 mg and 300 mg daily), either alone or in combination with
corticosteroids and other drugs (Table 3). Most of the women (n ¼ 23, 74%) received
corticosteroids. However, most of them in combination with thalidomide (n ¼ 15, 65%).
Four (13%) other women were treated with pentoxifylline monotherapy and two (6%) with
minocycline alone.
Adverse drug reactions (ADR) were registered for 36 (32%) patients, 22 (61%) of them
males. Thirty (46·9%) of the 64 individuals who received corticosteroids had ADR (Figure 1),
mainly glucose intolerance (n ¼ 15, 50%) and hypertension (n ¼ 10, 33·3%). Thalidomide
Table 1. The demographics, leprosy classification and treatment status of 112 patients diagnosed with ENL at the
Outpatient Clinic during 2005–2010
Characteristics
Number of patients
(%) or mean ^ sd
Gender Male 81 (72·3)
Female 31 (27·7)
Age (years)
Male Leprosy diagnosis 37·3 6 14·6
Female 37·2 6 16·8
Male ENL diagnosis 37·9 6 14·5
Female 38·0 6 16·8
Ridley-Jopling classification BL 19 (17·0)
LL 93 (83·0)
Leprosy treatment WHO MB MDT 91 (81·3)
Rifampicin and clofazimine 5 (4·5)
Rifampicin, clofazimine and ofloxacin 15 (13·4)
Rifampicin, clofazimine and minocycline 1 (0·8)
Timing of ENL Diagnosis Before MDT 28 (25·0)
During MDT 53 (47·3)
After MDT 31 (27·7)
ENL ¼ Erithema nodosum leprosum, BL ¼ borderline leprosy, LL ¼ lepromatous leprosy, WHO ¼ World
Health Organization, MB ¼ multibacillary, MDT ¼ multidrug therapy.
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was recorded as responsible for ADR in only six (0·6%) of the 98 individuals who received
the drug; constipation being their main complaint (n ¼ 5, 83%). Pentoxifylline, minocycline
and NSAIDs produced higher proportion of ADRs than thalidomide. Out of the 50 patients
that received pentoxifylline, only two (4%) had ADR, of the 29 patients that were treated with
minocycline, two women (7%) complained of ADR, and out of the 24 patients that received
NSAIDs, two (17%) patients had ADR.
14 (12·5%) patients required inpatient treatment at the Hospital, because of complications
of ENL such as secondary infection of skin lesions, lack of response to treatment or sepsis.
Ten of these patients were admitted during the first ENL episode.
Six patients (5%) died during the study period (Table 4). Four deaths occurred while
patients were taking treatment for ENL, all with thalidomide and corticosteroids. None of the
deaths could be considered directly caused by ENL or its treatment.
Table 3. ENL treatment during the first episode
Treatment
Gender Thalidomide Corticosteroids Thalidomide þ Corticosteroids Other drugs Total
Female 2 (6·5%) 8 (25·8%) 15 (48·4%) 6 (19·4%) 31 (100%)
Male 40 (49·4%) 0 (0·0%) 41 (50·6%) 0 81 (100%)
Total 42 (37·5%) 8 (7·1%) 56 (50·0%) 6 (5·4%) 112 (100%)
Other drugs: NSAIDs ¼ non-steroidal anti-inflammatory drugs, pentoxifylline, minocycline.
Table 2. Characteristics of first ENL episode ENL episode observed in 112 patients
Characteristics
Number (%)
or median [range]
ENL duration Acute 21 (18·8)
Chronic 91 (81·2)
Interval between first ENL treatment and last (months) All 35 [0·2–108·5]
Male 31·7 [0·2–108·5]
Female 39·2 [2·9–77·5]
Number of ENL recurrences 1 35 (85)
2 5 (12)
3 1 (2)
Clinical features of first ENL episode Skin lesions only 18 (16·1)
Oedema 63 (56·3)
Fever 52 (46·4)
Arthritis 46 (41·1)
Neuritis 34 (30·4)
Lymphadenopathy 31 (27·7)
Iritis 22 (19·6)
Orchitis 9 (11 of men)
Type of skin lesion on first ENL episode onset Nodules 106 (94·6)
Plaques 22 (19·6)
Papules 8 (7·1)
Skin lesion complications on first ENL episode Ulceration 5 (83)
Necrosis 1 (17)
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Discussion
This retrospective study demonstrates that ENL is a complication of leprosy associated with
morbidity in Brazil, but not with mortality. A much higher prevalence of ENL was observed
in this study as compared to previous ones. A systematic review of the epidemiological data
on ENL reported the average cumulative incidence in all MB patients of 1·2% (ranging from
0·2 in India and 4·6 in China).16 As a referral center, Souza Araujo Outpatient clinic receives
an elevated number of patients with late diagnosis and complications, hence the high
prevalence of ENL in our sample. In general, neither sex nor age are considered risk factors
for ENL.16 However, there is predominance of cases in young adult males, also observed in
our patients.
ENL can be considered a long lasting disease because most patients develop several
episodes over many years as observed by the present and other studies.7,17 A retrospective
study of 481 outpatients in India over a 11-year period showed that 8% of the ENL patients
had a single acute episode, a higher proportion than the 2·7% observed in our cohort.
However, we observed a higher proportion of chronic cases (81·2%) than Pocaterra et al. 7
that reported between 38–63% in 88 ENL cases. Recurrence of ENL episodes are a common
event as reported in the systematic review by Voorend and Post.16 Recurrences vary
according to the setting, in hospital-based studies, for instance, 39–77·3% of ENL patients
had multiple episodes (average of 2·6 per patient). We observed a lower proportion of
recurrence (36·6%) but similar mean number of episodes. Both chronicity and recurrence
Gastritis/epigastralgia; 7
Corticosteroid induced
lipodystrophy and other
Cushingoid features; 7
Hypertension; 10
Impaired glucose
tolerance; 15
Cataract; 2
Infections*; 2
Glaucoma; 1
Figure 1. Adverse drug reactions attributed to corticosteroids in 30 patients. *Infections: Strongyloidiasis and
dermatophyte infection.
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account for worsening of leprosy morbidity, even after release from MDT. This morbidity
constitutes a problem especially for young adults during their most productive period of life
and imposes a considerable service load to primary and reference health centers.
A large proportion of patients treated with thalidomide also required corticosteroids and
other additional drugs, but few of them were women (26·8%). Thalidomide was generally
well tolerated by the patients. A hospital-based study in Ethiopia, a country where
thalidomide is not available, described comorbidities after ENL diagnosis in 52% of the 96
cases that could be associated with corticosteroid therapy.12 Our results also show a high
rate of adverse effects associated with corticosteroids particularly glucose intolerance and
hypertension. It is well known the life-threatening risks long-term use of corticoids pose for
patients.18 It is noteworthy that 40% of this cohort did not require corticosteroids because
thalidomide alone adequately controlled their symptoms. Pentoxifylline, minocycline and
non-steroidal anti-inflammatory drugs, which are less effective for ENL control, also
produced ADRs. Although these alternative drugs produced a much higher proportion of
ADRs than thalidomide, their effects are mild.
ENL-associated mortality data are scarce. A retrospective study assessed mortality in
ENL patients in Ethiopia showed that 8% of 99 ENL cases died probably due to ENL or its
treatment.12 We observed a lower proportion of deaths (5·4%) in our cohort. The patient that
died from myocardial infarction had a medical history of diabetes, hypertension and smoking,
which increase the cardiovascular risk. A systematic review and meta-analysis on venous
thromboembolism in multiple myeloma patients, associated the use of thalidomide in
combination with dexamethasone to a risk of thromboembolism.19 Thus, the combination
between these drugs could add to the cardiovascular risk of ENL patients. There is need of a
prospective and systematic assessment of ADRs in patients with ENL. The development and
assessment of evidence-based guidelines for thalidomide, corticosteroids and other drugs in
ENL may facilitate the management of this challenging condition.
Suicide was the most common cause of death in a nation-wide leprosy mortality cross-
sectional study of 584 active leprosy cases in China.20 Among the 413 patients with known
cause of death, 86 committed suicide, 45% of them during the first 12 months of MDT. The
patient in our study committed suicide long after release from MDT. Shen et al.20 reported
four (2·8%) cases of death due to leprosy reaction, three of them occurring during the first
6 months of MDT and one after 24 months of treatment. Similarly, half of our cases died
during the same period. Unfortunately, the authors do not specify the type or characteristics of
the reactions, nor the source of the cause of death.
Leprosy has a low mortality rate, but in Brazil, it is more frequently registered as the
cause of death than malaria, which is an important cause of death among the infectious and
parasitic diseases worldwide. Between 2000–2011, 2,936 deaths were reported for leprosy
whereas during the same period, only 1,288 deaths by malaria were registered.21 As expected,
due to natural vulnerability, the highest mortality rates are observed in older age groups,21 – 23
as seen in our study. Interestingly, ENL occurs mainly in young adults.9 In the present study,
a high number of patients were women of childbearing age, which could be a problem for the
use of thalidomide due to its teratogenic effects.
In our study, no direct association could be observed between mortality and ENL
complications or its treatment because we had no access to the death certificates.
Nevertheless, ENL is not specifically registered in the International Statistical Classification
of Diseases and Related Health Problems (ICD-10). Only leprosy and its sequelae are found
(ICD A30 and B92, respectively).
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As a systemic disease, ENL may cause multiple organ involvement. Thus, making it
difficult to determine accurately the immediate, intermediate and underlying causes of
death23 such as are needed to be filled in Part I of the death certificate used in Brazil.24
Leprosy may also be included in Part II of the death certificate as another significant
conditions contributing to death but not resulting in the underlying cause. We did not have
reports of renal insufficiency or septicemia, which might have been the immediate causes of
death of some of the patients, and could be associated to complications of ENL or effect of its
chronic treatment. However, we did have reports of other common immediate causes of death
such as Cerebrovascular Accident and myocardial infarction. Probably, ENL is an under-
recognised cause of death.
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